PURPOSE: Absolute lymphocyte count recovery at day 15 (ALC-15) post-autologous stem cell transplantation (ASCT) is a powerful prognostic indicator for survival for multiple hematologic malignancies and metastatic breast cancer. The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown. EXPERIMENTAL DESIGN: We evaluated 145 consecutive patients with primary systemic amyloidosis who underwent ASCT at the Mayo Clinic from 1996 to 2003. The ALC-15 threshold was set at 500 cells/microL based on our previous observations. RESULTS: The median patient follow-up was 22 months (range, 3-87 months). Higher hematologic complete response was observed in patients with an ALC-15 > or = 500 cells/microL compared with patients with an ALC-15 < 500 cells/microL (41% versus 21%, P < 0.0008, respectively). The median overall survival and progression-free survival times were significantly better for the 59 patients that achieved an ALC-15 > or = 500 cells/microL compared with 86 patients with ALC-15 < 500 cells/microL (not reached versus 53 months, P < 0.0003 and not reached versus 27 months, P < 0.0001, respectively). Multivariate analysis showed ALC-15 to be an independent prognostic factor for overall survival and progression-free survival. CONCLUSIONS: ALC-15 > or = 500 cells/microL is associated with significantly improved clinical outcomes following ASCT in patients with primary systemic amyloidosis.
PURPOSE: Absolute lymphocyte count recovery at day 15 (ALC-15) post-autologous stem cell transplantation (ASCT) is a powerful prognostic indicator for survival for multiple hematologic malignancies and metastatic breast cancer. The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown. EXPERIMENTAL DESIGN: We evaluated 145 consecutive patients with primary systemic amyloidosis who underwent ASCT at the Mayo Clinic from 1996 to 2003. The ALC-15 threshold was set at 500 cells/microL based on our previous observations. RESULTS: The median patient follow-up was 22 months (range, 3-87 months). Higher hematologic complete response was observed in patients with an ALC-15 > or = 500 cells/microL compared with patients with an ALC-15 < 500 cells/microL (41% versus 21%, P < 0.0008, respectively). The median overall survival and progression-free survival times were significantly better for the 59 patients that achieved an ALC-15 > or = 500 cells/microL compared with 86 patients with ALC-15 < 500 cells/microL (not reached versus 53 months, P < 0.0003 and not reached versus 27 months, P < 0.0001, respectively). Multivariate analysis showed ALC-15 to be an independent prognostic factor for overall survival and progression-free survival. CONCLUSIONS: ALC-15 > or = 500 cells/microL is associated with significantly improved clinical outcomes following ASCT in patients with primary systemic amyloidosis.
Authors: A Kansagra; D J Inwards; S M Ansell; I N Micallef; P B Johnston; W J Hogan; S N Markovic; L F Porrata Journal: Bone Marrow Transplant Date: 2017-10-16 Impact factor: 5.483
Authors: Stefan O Ciurea; Victor Mulanovich; Ying Jiang; Roland Bassett; Gabriela Rondon; John McMannis; Marcos de Lima; Elizabeth J Shpall; Richard E Champlin Journal: Biol Blood Marrow Transplant Date: 2010-11-30 Impact factor: 5.742
Authors: Christopher G Kanakry; Allan D Hess; Christopher D Gocke; Christopher Thoburn; Ferdynand Kos; Christian Meyer; Janet Briel; Leo Luznik; B Douglas Smith; Hyam Levitsky; Judith E Karp Journal: Blood Date: 2010-10-08 Impact factor: 22.113
Authors: Luis F Porrata; David J Inwards; Ivana N Micallef; Patrick B Johnston; Stephen M Ansell; William J Hogan; Svetomir N Markovic Journal: Clin Dev Immunol Date: 2010-04-18
Authors: Luis F Porrata; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Dennis A Gastineau; Mark R Litzow; Jeffrey L Winters; Svetomir N Markovic Journal: Biol Blood Marrow Transplant Date: 2008-07 Impact factor: 5.742